Author
Listed:
- Ming Te Yeh
(University of California, San Francisco)
- Matthew Smith
(National Institute for Biological Standards and Control)
- Sarah Carlyle
(National Institute for Biological Standards and Control)
- Jennifer L. Konopka-Anstadt
(Division of Viral Diseases, Centers for Disease Control and Prevention
Center for Vaccine Innovation and Access, PATH)
- Cara C. Burns
(Division of Viral Diseases, Centers for Disease Control and Prevention)
- John Konz
(Center for Vaccine Innovation and Access, PATH)
- Raul Andino
(University of California, San Francisco)
- Andrew Macadam
(National Institute for Biological Standards and Control)
Abstract
Vaccination with Sabin, a live attenuated oral polio vaccine (OPV), results in robust intestinal and humoral immunity and has been key to controlling poliomyelitis. As with any RNA virus, OPV evolves rapidly to lose attenuating determinants critical to the reacquisition of virulence1–3 resulting in vaccine-derived, virulent poliovirus variants. Circulation of these variants within underimmunized populations leads to further evolution of circulating, vaccine-derived poliovirus with higher transmission capacity, representing a significant risk of polio re-emergence. A new type 2 OPV (nOPV2), with promising clinical data on genetic stability and immunogenicity, recently received authorization from the World Health Organization for use in response to circulating, vaccine-derived poliovirus outbreaks. Here we report the development of two additional live attenuated vaccine candidates against type 1 and 3 polioviruses. The candidates were generated by replacing the capsid coding region of nOPV2 with that from Sabin 1 or 3. These chimeric viruses show growth phenotypes similar to nOPV2 and immunogenicity comparable to their parental Sabin strains, but are more attenuated. Our experiments in mice and deep sequencing analysis confirmed that the candidates remain attenuated and preserve all the documented nOPV2 characteristics concerning genetic stability following accelerated virus evolution. Importantly, these vaccine candidates are highly immunogenic in mice as monovalent and multivalent formulations and may contribute to poliovirus eradication.
Suggested Citation
Ming Te Yeh & Matthew Smith & Sarah Carlyle & Jennifer L. Konopka-Anstadt & Cara C. Burns & John Konz & Raul Andino & Andrew Macadam, 2023.
"Genetic stabilization of attenuated oral vaccines against poliovirus types 1 and 3,"
Nature, Nature, vol. 619(7968), pages 135-142, July.
Handle:
RePEc:nat:nature:v:619:y:2023:i:7968:d:10.1038_s41586-023-06212-3
DOI: 10.1038/s41586-023-06212-3
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:nature:v:619:y:2023:i:7968:d:10.1038_s41586-023-06212-3. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.